The present invention relates to a pharmaceutical composition of a metabotropic glutamate 5 receptor (mGlu5) antagonist or a pharmacologically acceptable salt thereof. The composition contains a therapeutically active compound, a nonionic polymer and an ionic polymer, a binder and a filler in the form of matrix pellets, matrix tablets or coated pellets. The composition provides a pH-independent in vitro release profile of 70% NMT within 1 hour, 85% NMT within 4 hours, and 80% NLT within 8 hours. Such compositions are useful for the treatment of CNS disorders such as, for example, treatment-resistant depression (TRD) and fragile X chromosome syndrome.
展开▼
